Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pertuzumab

- PMLiVE

EFPIA says “indiscriminate” data transparency could be harmful

Comments come as European Parliament prepares to discuss clinical trial overhaul

- PMLiVE

Medicines key to new NHS Mandate, says ABPI

Government sets objectives for NHS Commissioning Board to improve patient care in England

Roche, social media and patients – part 1

UK pharma company talks about its digital patient group summit Share+

- PMLiVE

Researcher calls for Roche boycott over missing Tamiflu data

Nordic Cochrane Centre's Peter Gøtzsche also wants European governments to sue the pharma company for withholding data

- PMLiVE

NICE rejects Pierre Fabre’s bladder cancer drug Javlor

Says drug received final draft 'no' because pharma company failed to prove efficacy

- PMLiVE

Good practice in cancer care recognised at UK awards

Sir Mike Richards honoured with lifetime achievement award at QiC Excellence in Oncology 2012

- PMLiVE

NHS needs to invest for longer term savings, says ABPI

Chief executive Stephen Whitehead accuses health service of not seizing innovation

- PMLiVE

NICE to reverse approval for Novartis’ asthma drug Xolair

Draft guidance doesn't recommend omalizumab for severe asthma

- PMLiVE

India revokes Roche’s Pegasys patent after patient group challenge

Company becomes latest in big pharma to see intellectual property overturned

- PMLiVE

UK to amend and strengthen NHS constitution

Includes measures to involve patients in end-of-life care discussions

- PMLiVE

Roche’s Avastin cleared in EU for recurrent ovarian cancer

Becomes first biologic to win approval for platinum-sensitive ovarian cancer

- PMLiVE

Discounts persuade NICE to recommend skin cancer drugs Yervoy and Zelboraf

Roche and BMS offer patient access schemes for NHS use of drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links